|
Collaborations
No investor is going to pay for a 3 million dollar phase II or III trial, particularly when there are 800 pharmaceutical in the clinical trials pipeline and there are not enough clinical trial patients to go around.
The methodology of the assays is particularly stringent in that three different cell-death endpoints evaluate the activity of various drugs (up to 30) against the tumor (thus mostly the high cost).
If a laboratory were to perform both IHC and RLB endpoints on each specimen, the overall reliability of the end result would be greatly improved. But the standards of cell culture assays are particularly high.
I personally had thought about Craig Venter and wrote to him. Some have suggested PatientsLikeMe. I had initiated contact with James Heywood. Also Jay M. Tenenbaum of CollabRX.
|